Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
13 juin 2024 06h59 HE
|
Pasithea
Pasithea Therapeutics completes enrollment and initial dosing of Cohort 2 in its Phase 1 trial of PAS-004, with interim safety data expected in Q3 2024.
GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials
07 juin 2024 03h32 HE
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. In...
United States Clinical Trial Data Management Service Market Insights Report 2023-2028 Featuring Prominent Vendors - IQVIA,SYNEOS, ICON and Labcorp
21 nov. 2023 04h38 HE
|
Research and Markets
Dublin, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The "US Clinical Trial Data Management Service Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering. The US...
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
16 mars 2023 07h30 HE
|
Arbutus Biopharma Corporation
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical...
Global Hemophilia-A Clinical Trial Pipeline Report 2022
02 févr. 2023 13h38 HE
|
Research and Markets
Dublin, Feb. 02, 2023 (GLOBE NEWSWIRE) -- The "Global Hemophilia A Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.The report Hemophilia A...
Cellf BIO Begins Phase 1 Clinical Trial of BioSphincter™ Implant for Fecal Incontinence
05 janv. 2023 09h18 HE
|
CELLF-BIO, LLC
RICHMOND, Va., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cellf BIO, a biotechnology company that manufactures bioengineered sphincters using autologous progenitor cells, announced today that it has begun its...
IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
01 mars 2021 09h25 HE
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn, March 01, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has completed the first cohort of its Phase 1 clinical trial for...